Compare CANF & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANF | RVLV |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 1.8B |
| IPO Year | 2011 | 2018 |
| Metric | CANF | RVLV |
|---|---|---|
| Price | $3.63 | $22.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $9,750.00 | $29.75 |
| AVG Volume (30 Days) | 634.9K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.64 |
| EPS | N/A | ★ 0.86 |
| Revenue | N/A | ★ $1,225,682,000.00 |
| Revenue This Year | $461.72 | $10.96 |
| Revenue Next Year | $290,391.28 | $8.01 |
| P/E Ratio | ★ N/A | $26.52 |
| Revenue Growth | N/A | ★ 8.48 |
| 52 Week Low | $0.17 | $16.80 |
| 52 Week High | $10.40 | $31.68 |
| Indicator | CANF | RVLV |
|---|---|---|
| Relative Strength Index (RSI) | 40.57 | 37.52 |
| Support Level | $0.60 | $20.05 |
| Resistance Level | $4.74 | $24.54 |
| Average True Range (ATR) | 0.71 | 1.31 |
| MACD | -0.19 | -0.07 |
| Stochastic Oscillator | 1.16 | 17.44 |
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.